Yunnan Baiyao Group (000538) H1 2025 earnings summary

Executive summary

• Operating revenue for H1 2025 reached RMB 21.26 billion, up 3.92% year-over-year; net profit attributable to shareholders was RMB 3.63 billion, up 13.93% year-over-year, both hitting record highs for the period.

• Net operating cash flow increased 21.45% year-over-year to RMB 3.96 billion; weighted average ROE rose to 9.09%, up 1.16 percentage points.

• Industrial revenue share increased to 40.01% of total revenue, up 2.6 percentage points year-over-year, with industrial revenue growing 11.13%.

• The company maintained a healthy asset structure, with total assets of RMB 54.54 billion and an asset-liability ratio of 25.91%.

Financial highlights

• Operating revenue: RMB 21.26 billion (+3.92% YoY); net profit attributable to shareholders: RMB 3.63 billion (+13.93% YoY).

• Net profit after deducting non-recurring items: RMB 3.46 billion (+10.40% YoY).

• Net cash flows from operating activities: RMB 3.96 billion (+21.45% YoY).

• Basic and diluted EPS: RMB 2.04 (+13.97% YoY); weighted average ROE: 9.09%.

• Gross margin for industrial sales: 67.93%; commercial sales: 6.06%.

• Special dividend of RMB 10.19 per 10 shares, representing 50.05% of H1 2025 net profit.

Outlook and guidance

• The company will continue to focus on high-quality growth, digital transformation, and international expansion.

• Strategic focus on pharmaceuticals, health products, TCM resources, and commercial logistics, with ongoing investment in R&D and digitalization.

• Plans to further enhance operational efficiency, supply chain management, and product innovation.